| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/14/2011 | CA2777085A1 Combination |
| 04/14/2011 | CA2776919A1 Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin b12 and vitamin b6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing |
| 04/14/2011 | CA2776842A1 Pyrazole derivatives as modulators of calcium release-activated calcium channel |
| 04/14/2011 | CA2776308A1 Purine derivatives useful as hsp90 inhibitors |
| 04/14/2011 | CA2776260A1 P-glycoprotein-specific non-competitive peptide and peptidomimetic modulators |
| 04/14/2011 | CA2775793A1 Siglec 15 antibodies in treating bone loss-related disease |
| 04/14/2011 | CA2775747A1 Methods and compositions related to clot-binding lipid compounds |
| 04/14/2011 | CA2775634A1 Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer |
| 04/14/2011 | CA2774953A1 Human domain antibodies against components of the human insulin-like growth factor (igf) system |
| 04/14/2011 | CA2773676A1 Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof |
| 04/14/2011 | CA2773576A1 Apogossypolone derivatives as anticancer agents |
| 04/13/2011 | EP2308996A1 Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis |
| 04/13/2011 | EP2308989A2 Pectin hydrolysis products |
| 04/13/2011 | EP2308987A2 Improved transfection of eukaryotic cells with linear polynucleotides by electroporation |
| 04/13/2011 | EP2308916A1 Polymer/metal complex composite having mri contrast ability and mri contrasting and/or antitumor composition using the same |
| 04/13/2011 | EP2308898A1 Internalizing anti-CD74 antibodies and methods of use |
| 04/13/2011 | EP2308897A1 Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
| 04/13/2011 | EP2308885A2 Novel compounds and methods for therapy |
| 04/13/2011 | EP2308879A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| 04/13/2011 | EP2308877A1 Imidazopyridin-2-on derivative |
| 04/13/2011 | EP2308868A1 Histone deacetylase inhibitors and uses thereof |
| 04/13/2011 | EP2308861A1 Macrocyclic compounds useful as pharmaceuticals |
| 04/13/2011 | EP2308855A1 2,4-Diaminopyrimidine derivatives |
| 04/13/2011 | EP2308846A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308845A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308844A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308842A1 Pharmaceutical compositions |
| 04/13/2011 | EP2308833A2 Cyclic protein tyrosine kinase inhibitors |
| 04/13/2011 | EP2308515A1 Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors |
| 04/13/2011 | EP2308508A1 Photodynamic therapy using chemoluminescence and a ligand-photosensitiser conjugate |
| 04/13/2011 | EP2308467A2 Liquid pharmaceutical formulations of docetaxel |
| 04/13/2011 | EP2307425A1 Imidazothiadiazoles derivatives |
| 04/13/2011 | EP2307422A1 Novel spirochromanone carboxylic acids |
| 04/13/2011 | EP2307421A1 Oxindole compounds |
| 04/13/2011 | EP2307416A2 Substituted tricyclic derivatives against neurodegenerative diseases |
| 04/13/2011 | EP2307414A2 Pi3k isoform selective inhibitors |
| 04/13/2011 | EP2307412A2 Heterocyclic derivatives as modulators of ion channels |
| 04/13/2011 | EP2307409A1 Pyrrolopyridines as kinase inhibitors |
| 04/13/2011 | EP2307401A2 Antineoplastic derivatives of 4-oxo-1,4-dihydro-quinoline, preparation thereof, and therapeutic use thereof |
| 04/13/2011 | EP2307400A2 Inhibitors of pi3 kinase |
| 04/13/2011 | EP2307385A1 2 -arylaminoquinazolines for treating proliferative diseases |
| 04/13/2011 | EP2307376A1 Novel phenylamino isonicotinamide compounds |
| 04/13/2011 | EP2307367A2 Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
| 04/13/2011 | EP2307364A1 Isoindolone derivatives as mek kinase inhibitors and methods of use |
| 04/13/2011 | EP2307342A1 Diglycidic ether derivative therapeutics and methods for their use |
| 04/13/2011 | EP2307052A2 Anti-beta-2-microglobulin agents and the use thereof |
| 04/13/2011 | EP2307050A1 Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
| 04/13/2011 | EP2307041A2 Dosing regimen |
| 04/13/2011 | EP2307033A2 Use of oncolytic herpes viruses for killing cancer stem cells |
| 04/13/2011 | EP2307025A2 Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| 04/13/2011 | EP2307012A1 Nitrogen heterocycle derivatives as proteasome modulators |
| 04/13/2011 | EP2307010A1 Thiazole compounds, and compositions and methods using same |
| 04/13/2011 | EP2307003A2 Combination therapy with pm00104 and another antitumor agent |
| 04/13/2011 | EP2307002A1 Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine |
| 04/13/2011 | EP2306996A1 Use of hdac inhibitors for the treatment of hodgkin's disease |
| 04/13/2011 | EP2306995A1 Antitumor properties of no modified protease inhibitors |
| 04/13/2011 | EP2306978A2 Compositions for the in vivo delivery of rnai agents |
| 04/13/2011 | EP2013198B1 Solid-state form of amg 706 and pharmaceutical compositions thereof |
| 04/13/2011 | EP1931636B1 Isoquinolines as igf-1r inhibitors |
| 04/13/2011 | EP1909800B1 Acylglycerophospholipids for treating symptoms concomitant with cancer |
| 04/13/2011 | EP1796644B1 Drug delivery from embolic agents |
| 04/13/2011 | EP1542978B1 Novel bio-active molecules |
| 04/13/2011 | EP1539783B1 Inhibitors of nucleoside phosphorylases and nucleosidases |
| 04/13/2011 | EP1539763B1 Azaindole kinase inhibitors |
| 04/13/2011 | EP1412485B1 Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| 04/13/2011 | EP1237584B1 Receptor binding conjugates |
| 04/13/2011 | EP0957941B1 USE OF A MELANOMA DIFFERENTIATION ASSOCIATED GENE (mda-7) FOR REVERSING A CANCEROUS PHENOTYPE |
| 04/13/2011 | CN1980690B Malignant tumor local infiltration inhibitor containing batroxobin |
| 04/13/2011 | CN1939296B Theapolyphenol composition and its preparation |
| 04/13/2011 | CN1768873B Apparatus and method for electroporation mediated delivery for drugs and genes |
| 04/13/2011 | CN1763097B Polypeptide variants with altered effector function |
| 04/13/2011 | CN1759123B Uses of IL-23 agonists and antagonists, related reagents |
| 04/13/2011 | CN1693415B Hydroxy phosphorite of near infrared fluorescence quantum point mark and its preparation process and application |
| 04/13/2011 | CN1649902B Internalizing anti-CD74 antibodies and methods of use |
| 04/13/2011 | CN1379820B Lentiviral vectors for preparation of immunotherapeutical compositions |
| 04/13/2011 | CN102015753A Hydrophobic modified preS-derived peptides of hepatitis b virus (HBV) and their use as vehicles for the specific delivery of compounds to the liver |
| 04/13/2011 | CN102015751A Process to produce fibrillar proteins and method of treating using fibrillar proteins |
| 04/13/2011 | CN102015743A Ruthenium compounds and compositions |
| 04/13/2011 | CN102015739A Novel compounds and methods for therapy |
| 04/13/2011 | CN102015728A Thiazolyl-dihydro-indazoles |
| 04/13/2011 | CN102015719A Pyrrolotriazine kinase inhibitors |
| 04/13/2011 | CN102015716A Imidazo [1,2-b] pyridazine derivatives for the treatment of C-MET tyrosine kinase mediated disease |
| 04/13/2011 | CN102015713A Inhibitors of protein kinases |
| 04/13/2011 | CN102015708A Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| 04/13/2011 | CN102015707A RAF inhibitor compounds and methods of use thereof |
| 04/13/2011 | CN102015705A Fused heterocyclic derivative and use thereof |
| 04/13/2011 | CN102015701A PIM kinase inhibitors and methods of their use |
| 04/13/2011 | CN102015694A Pyridazinone derivatives |
| 04/13/2011 | CN102015686A Novel heterocyclic compounds and uses therof |
| 04/13/2011 | CN102015681A Crystal form of phenylamino pyrimidine derivatives |
| 04/13/2011 | CN102015678A Fused pyridines active as inhibitors of c-Met |
| 04/13/2011 | CN102015676A Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators |
| 04/13/2011 | CN102015660A 2-aminoquinazoline derivative |
| 04/13/2011 | CN102015656A Phenylpropionic acid derivative and use thereof |
| 04/13/2011 | CN102015644A Hydroxyalkanyl amides as modulators of chemokine receptor activity |
| 04/13/2011 | CN102015639A Compounds for use in stabilizing p53 mutants |
| 04/13/2011 | CN102015638A Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient |
| 04/13/2011 | CN102015027A Microrna signatures associated with human chronic lymphocytic leukemia (CCL) and uses thereof |
| 04/13/2011 | CN102014969A Contrast agents for applications including perfusion imaging |
| 04/13/2011 | CN102014968A Therapy selection method |